Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

693 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Italian Survey on adjuvant treatment of non-small cell lung cancer (ISA).
Banna GL, Di Maio M, Follador A, Collovà E, Menis J, Novello S, Bria E; ISA Co-Authors; Airoldi M, Amoroso D, Ardizzoia A, Aurilio G, Bajetta E, Ballardini P, Barbieri F, Barletta E, Balzelloni ML, Basso U, Bernardini I, Boni C, Bordin V, Bretti S, Bronte G, Brunetti C, Buti S, Capanna L, Colombo A, Condemi G, Cortinovis D, Dambrosio M, Di Fonzo C, Di Lucca G, Dima G, Falzetta A, Favaretto A, Ferraù F, Garetto L, Gebbia V, Genestreti G, Gentile AL, Giovanardi F, Labianca R, Lorusso V, Mantovani G, Martelli O, Massari F, Mazzoli M, Michetti G, Mordenti P, Mucciarini C, Munao S, Nacci A, Pogliani C, Procopio G, Riccardi F, Rizzato S, Rossi A, Rosti G, Russo P, Saladino T, Salesi N, Santangelo D, Sava T, Savarino A, Spinnato F, Tiseo M, Tomassi O, Tondulli L, Tonini G, Turano S, Valerio MR, Verderame F, Zanelli F, Zanon E. Banna GL, et al. Among authors: barbieri f. Lung Cancer. 2011 Jul;73(1):78-88. doi: 10.1016/j.lungcan.2010.10.020. Epub 2010 Dec 8. Lung Cancer. 2011. PMID: 21144614
BE-POSITIVE: Beyond progression after tyrosine kinase inhibitor in EGFR- positive non small cell lung cancer patients: Results from a multicenter Italian observational study.
Vavalà T, Follador A, Tiseo M, Galetta D, Morabito A, Di Maio M, Martelli O, Caffo O, Piovano PL, Cortinovis D, Zilembo N, Casartelli C, Banna GL, Ardizzoia A, Barzelloni ML, Bearz A, Genestreti G, Mucciarini C, Filipazzi V, Menis J, Rizzo E, Barbieri F, Rijavec E, Cecere F, Bria E, Spitaleri G, Rossi A, Novello S. Vavalà T, et al. Among authors: barbieri f. Lung Cancer. 2016 May;95:73-81. doi: 10.1016/j.lungcan.2016.02.011. Epub 2016 Feb 26. Lung Cancer. 2016. PMID: 27040855 Free article.
Outcomes of First-Generation EGFR-TKIs Against Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Post Hoc Analysis of the BE-POSITIVE Study.
Pilotto S, Rossi A, Vavalà T, Follador A, Tiseo M, Galetta D, Morabito A, Di Maio M, Martelli O, Caffo O, Piovano PL, Cortinovis D, Zilembo N, Casartelli C, Banna GL, Ardizzoia A, Barzelloni ML, Bearz A, Genestreti G, Mucciarini C, Filipazzi V, Menis J, Rizzo E, Barbieri F, Rijavec E, Cecere F, Spitaleri G, Bria E, Novello S. Pilotto S, et al. Among authors: barbieri f. Clin Lung Cancer. 2018 Jan;19(1):93-104. doi: 10.1016/j.cllc.2017.05.016. Epub 2017 Jun 1. Clin Lung Cancer. 2018. PMID: 28645631
Be-TeaM: An Italian real-world observational study on second-line therapy for EGFR-mutated NSCLC patients.
Reale ML, Chiari R, Tiseo M, Vitiello F, Barbieri F, Cortinovis D, Ceresoli GL, Finocchiaro G, Romano GD, Piovano PL, Del Conte A, Borra G, Verderame F, Scotti V, Nonnis D, Galetta D, Sergi C, Migliorino MR, Tonini G, Cecere F, Berardi R, Pino MS, Martelli O, Gelibter A, Carta A, Vattemi E, Pagano M, Zullo A, Ferrari S, Rossi A, Novello S. Reale ML, et al. Among authors: barbieri f. Lung Cancer. 2020 Feb;140:71-79. doi: 10.1016/j.lungcan.2019.12.006. Epub 2019 Dec 16. Lung Cancer. 2020. PMID: 31884129
Informal caregiving burden in advanced non-small cell lung cancer: the HABIT study.
Gridelli C, Ferrara C, Guerriero C, Palazzo S, Grasso G, Pavese I, Satta F, Bajetta E, Cortinovis D, Barbieri F, Gebbia V, Grossi F, Novello S, Baldini E, Gasparini G, Latino W, Durante E, Giustini L, Negrini C. Gridelli C, et al. Among authors: barbieri f. J Thorac Oncol. 2007 Jun;2(6):475-80. doi: 10.1097/01.JTO.0000275342.47584.f3. J Thorac Oncol. 2007. PMID: 17545841 Free article.
A randomized phase II trial evaluating standard (50 mg/min) versus low (10 mg/min) infusion duration of gemcitabine as first-line treatment in advanced non-small-cell lung cancer patients who are not eligible for platinum-based chemotherapy.
Cappuzzo F, Novello S, De Marinis F, Selvaggi G, Scagliotti GV, Barbieri F, Maur M, Papi M, Pasquini E, Bartolini S, Marini L, Crinò L. Cappuzzo F, et al. Among authors: barbieri f. Lung Cancer. 2006 Jun;52(3):319-25. doi: 10.1016/j.lungcan.2006.03.004. Epub 2006 Apr 19. Lung Cancer. 2006. PMID: 16630670 Clinical Trial.
Pemetrexed versus pemetrexed and carboplatin as second-line chemotherapy in advanced non-small-cell lung cancer: results of the GOIRC 02-2006 randomized phase II study and pooled analysis with the NVALT7 trial.
Ardizzoni A, Tiseo M, Boni L, Vincent AD, Passalacqua R, Buti S, Amoroso D, Camerini A, Labianca R, Genestreti G, Boni C, Ciuffreda L, Di Costanzo F, de Marinis F, Crinò L, Santo A, Pazzola A, Barbieri F, Zilembo N, Colantonio I, Tibaldi C, Mattioli R, Cafferata MA, Camisa R, Smit EF. Ardizzoni A, et al. Among authors: barbieri f. J Clin Oncol. 2012 Dec 20;30(36):4501-7. doi: 10.1200/JCO.2012.43.6758. Epub 2012 Oct 29. J Clin Oncol. 2012. PMID: 23109689 Clinical Trial.
693 results